Finanzas de Tarsus Pharmaceuticals Inc (TARS)TARSTarsus Pharmaceuticals Inc

Evaluating the bottom line, Tarsus Pharmaceuticals, Inc. maintains a gross margin of 93.03%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11.45%, while the net margin is -10.67%. These profitability ratios, combined with a Return on Equity (ROE) of -13.68%, provide a clear picture of how effectively TARS converts its operational activities into shareholder value.

In the context of the broader market, TARS competes directly with industry leaders such as IDYA and ACAD. With a market capitalization of $3.19B, it holds a significant position in the sector. When comparing efficiency, TARS's gross margin of 93.03% stands against IDYA's 100.00% and ACAD's 90.81%. Such benchmarking helps identify whether Tarsus Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Tarsus has shown strong revenue growth, with Q2 2026 net product sales of $173.9 million and a gross margin of approximately 93%. However, it continues to report net losses, with a net income of -$18.55 million in Q2 2026, reflecting ongoing challenges in achieving profitability.